English 
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00
Anti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
Description
Development of Anti Neutralizing Antibodies (NAbs) is currently the most serious complication during the Gene Therapy treatment, as it makes replacement therapy ineffective and occurs in approximately 30% and 5% of patients. Tremendous progress has been achieved in the last several years in overcoming this formidable barrier and extending therapy to patients who have pre-existing neutralizing antibodies, either because of infection with wild-type AAV or prior treatment with an AAV vector.
In this report, Mellalta Meets provides an in-depth analyzes anti-Nabs gene therapies covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy area, investments, and acquisition trends. Currently, there are more than 20 candidate anti-Nabs gene therapies products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Sarepta Therapeutics, UniQure, Spark Therapeutics and many more which have robust clinical pipeline of anti-Nabs gene therapies candidates.
As per analysis, the development pipeline is full of different technological aspect which can help in redosing, suppressing the neutralizing antibodies as well as ability to give gene therapies even in presence of Nabs.
Key Highlights of Anti Neutralizing Antibodies (NAbs) Gene Therapies Report
- There are ~11 products in the Preclinical stage of development, representing 48% of the total share of the developing neutralizing antibodies (NAbs) landscape. Remaining 52% has been contributed by Phase I/II (35%); Phase II (9%); Phase III & Phase I (4%).
- The pipeline of Neutralizing Antibodies is dominated by biotech companies headquartered in the United States with the American companies holding the top ten positions. They represent ~95% of all the pipeline Neutralizing Antibodies in clinical stages.
- Metabolic Disorders represents ~ 35% of the total NAbs therapies while the therapy areas namely Ophthalmology (22%); Mental, Behavioural and Neurodevelopmental disorders (13%); Musculoskeletal Diseases (13%); Hematology (9%); CNS Disorder (4%) and Respiratory Diseases (4%) occupy the remaining therapy area of Neutralizing antibodies (NAbs).
- The pipeline of Neutralizing Antibodies (NAbs) therapies is dominated by the Preclinical (11); Phase I/II (8); Phase II (2) assets and Phase I & Phase III (1) assets.
- To be continued…
Report Coverage:
- Indication Prioritisation: Anti Neutralizing Antibodies (NAbs) Gene Therapies market potential based on Indications
- Business Transactions & Strategies: Key collaborations and deal values
- Anti Neutralizing Antibodies (NAbs) Gene Therapies Pipeline Development: Product Profiles, Clinical Trials & Results
- Anti Neutralizing Antibodies (NAbs) Gene Therapies Acquisition Targets
- Anti Neutralizing Antibodies (NAbs) Gene Therapies Competitive Intelligence
- Recent & Upcoming events
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- REPORT OVERVIEW
- OVERVIEW
- Neutralizing Antibodies (NAbs) Against AAV- Overview
- Diagnostic tools for Nabs detection
- Diagnostic tools for NAbs detection: Limitations
- Current Challenges with NAbs in Gene Therapy
- Methods of circumventing NAbs in Gene therapy
- ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE ANALYSIS BY PHASES
- Overview
- Assets by Indication/Phase
- Pipeline Products by Stage of Development
- Neutralizing Antibodies Competitive Landscape
- Pipeline Products by Company and Phases
- Pipeline Products by Therapy Area
- Pipeline Products by Indication and Phases
- Neutralizing Antibodies (NAbs) Clinical & Regulatory Timelines
- ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES ACQUISITIONS,LICENSING AND COLLABORATION DEALS
- Neutralizing Antibodies (NAbs) Acquisitions, Licensing and Deal values
- Neutralizing Antibodies (NAbs) Acquisitions, Licensing by Transaction type and total amount size by Phases
- Promising Technology Under development
- ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE LANDSCAPE
- Profile at Glance
- Late-Stage Assets Comparisons At–a–glance
- Neutralizing Antibodies (NAbs) Pipeline Drug Profiles
- Phase III
- uniQure: AMT-061
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- uniQure: AMT-061
- Phase III
- Phase II
- Sarepta Therapeutics/Roche:SRP-9001
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Sarepta Therapeutics/Roche:SRP-9001
-
-
-
-
- Sarepta Therapeutics: SRP-5051
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Sarepta Therapeutics: SRP-5051
-
-
-
- Phase I/II
- Spark Therapeutics/Roche: SPK-8016
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Taysha Gene Therapies: TSHA -101
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- 4D Molecular Therapeutics: 4D-125
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Editas Medicine: EDIT-101
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- 4D Molecular Therapeutics:4D-310
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Asklepios BioPharmaceutical: ACT-101
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Passage Bio: PBGM-01
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Astellas Gene Therapies: AT-845
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Phase I
- 4D Molecular Therapeutics: 4D-110
- Product Profile & Description
- Collaborations
- Other Developments
- Clinical Trials
- Preclinical
- Abeona Therapeutics: ABO-401
- Product Profile & Description
- Collaborations
- Other Developments
- Abeona Therapeutics: ABO-50X
- Product Profile & Description
- Collaborations
- Other Developments
- Selecta Biosciences: MMA-101
- Product Profile & Description
- Collaborations
- Other Developments
- Taysha Gene Therapies: TSHA-102
- Product Profile & Description
- Collaborations
- Other Developments
- Taysha Gene Therapies: TSHA-103
- Product Profile & Description
- Collaborations
- Other Developments
- Taysha Gene Therapies: TSHA-104
- Product Profile & Description
- Collaborations
- Other Developments
- 4D Molecular Therapeutics:4D-150
- Product Profile & Description
- Collaborations
- Other Developments
- Hansa Biopharma AB/Sarepta Therapeutics:Imlifidase
- Product Profile & Description
- Collaborations
- Other Developments
- 4D Molecular Therapeutics:4D-710
- Product Profile & Description
- Collaborations
- Other Developments
- LogicBio Therapeutics:AAV sL65 Capsid
- Product Profile & Description
- Collaborations
- Other Developments
- StrideBio: STRX-110
- Product Profile & Description
- Collaborations
- Other Developments
- Other Drugs
- Product Profile & Description
- Collaborations
- Other Developments
- Spark Therapeutics/Roche: SPK-8016
- ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES MARKET OVERVIEW
- Current Market Scenario
- Market Potential of Neutralizing Antibodies Market
- Market Potential of Neutralizing Antibodies Market Barriers & Challenges
- ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES FUTURE PROSPECTS
- SWOT ANALYSIS
- APPENDIX
Sample Enquiry
Related products
-
Complex regional pain syndrome (CRPS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsComplex regional pain syndrome (CRPS) is a chronic pain condition characterized by spontaneous and evoked regional pain, usually starting in a distal extremity, which is disproportionate in magnitude or duration to the typical pain course after similar tissue trauma. Current treatment for CRPS requires a multidisciplinary approach involving patient education, physical and occupational therapy, psychiatry and pain medicine specialists, along with pharmacological and surgical interventions. Unfortunately, the current available treatment options are generally considered to be ineffective and one-dimensional, as they only treat part of the disease. Emerging therapies like Soticlestat (Takeda / Ovid Therapeutics and Lanicemine (AstraZeneca / Biohaven Pharmaceuticals) is expected to generate more market share than other emerging therapies and have the potential to overcome the treatment barrier.
-
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2022 to 2032. In 2022, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2018 to 2032.
-
Lumbar Radiculopathy (Sciatica)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).
-
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032